



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Desponts
Art Unit	1632 1635
Examiner Name	

Attorney Docket Number **USF-212XZ1T**

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
83	U1	US-10/605,452	09-30-2003	Kerr et al.	All
	U2	US-10/904,667	11-22-2004	Kerr et al.	All
	U3	US-2002/0137711 A1	09-26-2002	Kerr	All
	U4	US-2002/0165192 A1	11-07-2002	Kerr et al.	All
	U5	US-4,603,112	07-29-1986	Paoletti et al.	All
	U6	US-4,769,330	09-06-1988	Paoletti et al.	All
	U7	US-4,777,127	10-11-1988	Suni et al.	All
	U8	US-5,017,487	05-21-1991	Stunnenberg et al.	All
	U9	US-5,168,057	11-24-1992	Palese et al.	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
83	F1	WO 89/01973 A2	03-09-1989	Applied Biotech. Inc.	All	
	F2	WO 91/02805 A2	03-07-1991	Viagene, Inc.	All	
	F3	WO 92/06693 A1	04-30-1992	Fox Chase Cancer Ctr.	All	
	F4	WO 97/10252 A1	03-20-1997	Fred Hutchinson Cancer Research	All	
	F5	WO 97/12039 A2	04-03-1997	Krystal	All	
	F6	EP 0 345 242 A2	12-06-1989	Smithkline Biologicals	All	

Examiner
Signature

83 —

Date
Considered

02
10-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (MPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Desponts
Art Unit	1622 1635
Examiner Name	

Attorney Docket Number **USF-212XZ1T****U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>JZ</i>	U10	US-6,090,621	07-18-2000	Kavanaugh et al.	All
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
<i>JZ</i>	F7	EP 0 440 219 A1	08-07-1991	Schweiz, Serum- & Impfstitut Bern	All	
<i>JZ</i>	F8	GB 2 200 651	08-10-1988	Khalaf Al-Sumidale	All	
	F9					
	F10					
	F11					
	F12					

Examiner Signature *JZ*Date Considered *10-10-07*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	6	Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Desponts
				Group Art Unit	1632 / 635
				Examiner Name	
				Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JZ	R1	AGRAWAL, S. "Antisense oligonucleotides: towards clinical trials" <i>TIBTECH</i> , 1996, 14:376-387.	
	R2	AGRAWAL, S. and KANDIMALLA, E. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , 2000, 6:72-81.	
	R3	AKAGI, K. et al. "Cre-mediated somatic site-specific recombination in mice" <i>Nucleic Acids Res</i> , 1997, 25(9):1766-1773.	
	R4	BENDER, M.A. et al. "Description and targeted deletion of 5' hypersensitive site 5 and 6 of the mouse β -globin locus control region" <i>Blood</i> , 1998, 92:4394-4403.	
	R5	BRAASCH, D.A. and COREY, D.R. "Novel antisense and peptide nucleic acid strategies for controlling gene expression" <i>Biochemistry</i> , 2002, 41(14):4503-4510.	
	R6	BRANCH, A. "A good antisense molecule is hard to find" <i>Trends in Biochem.</i> , 1998, 23:45-50.	
	R7	CANTLEY, L.C. et al. "Oncogenes and signal transduction" <i>Cell</i> , 1991, 64:281-302.	
	R8	CHIRILA, T. et al. "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides" <i>Biomaterials</i> , 2002, 23:321-342.	
	R9	CROOKE, S.T. "Basic principles of antisense therapeutics" in <i>Antisense Res. and Application</i> , chapter 1, pgs 1-50, S. Crooke, Ed., Springer-Verlag, 1999.	
	R10	DESPONTS, C. et al. "MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival" <i>FASEB Journal</i> , March 20, 2002, 16(4):A706, abstract.	
	R11	EVANS, D.J. et al. "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies" <i>Nature</i> , 1989, 339:385-388.	
	R12	FISHER-HOCH, S.P. et al. "Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene" <i>PNAS</i> , 1989, 86:317-321.	
	R13	GEWIRTZ, A.M. et al. "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:3161-3163.	

Examiner Signature	93	Date Considered	11-10-07
--------------------	----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	6	Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Desponts
				Group Art Unit	1622 1635
				Examiner Name	
				Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
JZ	R14	GHANSAH, T. et al. "A role for the SH2-containing Inositol phosphatase in the biology of natural killer cells and stem cells" <i>Activating and Inhibitory Immunoglobulin-like Receptors</i> , 2001, pp. 129-140.			
1	R15	GHANSAH, T. et al. "Target disruption of Src homology 2-containing 5' inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells" <i>FASEB Journal</i> , March 20, 2002, 16(4):A706, abstract.			
	R16	GHANSAH, T. et al. "The Src homology 2 containing inositol phosphatase is vital for the function and homeostasis of Natural Killer cells" <i>FASEB Journal</i> , March 7, 2001, 15(4):A655, abstract.			
	R17	GUZMAN, R.J. et al. "Molecular and cellular cardiology/receptors: efficient and selective adenovirus-mediated gene transfer into vascular neointima" <i>Circulation</i> , 1993, 88(6):2838-2848.			
	R18	HAWKINS, P.T. et al. "Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P ₃ by activating a PtdIns(4,5)P ₂ 3-OH kinase" <i>Nature</i> , 1992, 358:157-910.			
	R19	HELD, W. et al. "Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection" <i>J. Exp. Med.</i> , 1996, 184(5):2037-2041.			
	R20	HELGASON, C.D. et al. "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span" <i>Genes & Dev.</i> , 1998, 12(11):1610-1620.			
	R21	HUBER, M. et al. "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation" <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95(19):11330-11335.			
	R22	JEFFERSON, A.B. et al. "Properties of type II inositol polyphosphate 5-phosphatase" <i>J. Biol. Chem.</i> , 1995, 270(16):9370-9377.			
	R23	JEN, K-Y and GEWIRTZ, A.M. "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies" <i>Stem Cells</i> , 2000, 18:307-319.			
	R24	JOLLY, D. et al. "Viral vector systems for gene therapy" <i>Cancer Gene Therapy</i> , 1998, 1(1):51-64.			
	R25	KASS-EISLER, A. et al. "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo" <i>PNAS</i> , 1993, 90:11498-11502.			
	R26	KERR, WILLIAM G. et al. Critical Role for SHIP in engraftment of histo-incompatible stem cells, <i>Oncology Research</i> , 2001, 12:285.			

Examiner Signature		Date Considered	11-10-07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
Sheet	5	of	6	Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Desponts
				Group Art Unit	1632 / 635
				Examiner Name	
				Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
J 3	R27	KLIPPEL, A. et al. "Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways" <i>Mol. Cell. Biol.</i> , 1996, 16(8):4117-4127.			T ²
	R28	KOH, C. et al. "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo" <i>Blood</i> , 2001, 97(10):3132-3137.			
	R29	KOLLS, J. et al. "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer" <i>PNAS</i> , 1994, 91:215-219.			
	R30	LANIER, L.L. "NK cell receptors" <i>Annual Rev of Immunology</i> , 1998, 16:359-393.			
	R31	LIU, L. et al. "The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis" <i>J. Biol. Chem.</i> , 1997, 272:8983-8988.			
	R32	LIU, Q. et al. "SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell-survival" <i>Genes & Dev.</i> , 1999, 13(7):786-791.			
	R33	LIU, Q. et al. "The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B cell antigen receptor signaling" <i>J. Exp. Med.</i> , 1998, 188(7):1333-1342.			
	R34	LOTZOVA, E. et al. "Prevention of Rejection of Allogeneic Bone Marrow Transplants by NK-1.1 Anti Serum" <i>Transplantation</i> , 1983, 35(5):490-494.			
	R35	LUCAS, D.M. and ROHRSCHEIDER, L. "A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development" <i>Blood</i> , 1999, 93(6):1922-1933			
	R36	OKADA, H. et al. "Cutting edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca ²⁺ oscillatory response" <i>J. Immunol.</i> , 1998, 161:5192-5132.			
	R37	OVERBAUGH, J. et al. "Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats" <i>Science</i> , 1988, 239:906-910.			
	R38	PALU, G. et al. "In pursuit of new developments for gene therapy of human diseases" <i>J. Biotech</i> , 1999, 68:1-13.			
↓	R39	PIHL-CAREY, K. "Disease drug fails in phase III" <i>BioWorld Today</i> , 1999, 10:1-2.			

Examiner Signature	J 3	Date Considered	11-10-67
--------------------	-----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	6	of	6	Attorney Docket Number	USF-212XZ1T
-------	---	----	---	------------------------	-------------

Complete if Known

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Desponts
Group Art Unit	1632
Examiner Name	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Q3	R40	POZNANSKY, M. et al. "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector" <i>J. Virol.</i> , 1991, 65:532-536.	
	R41	RUGGERI, L. et al. "Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation" <i>Blood</i> , 1999, 94(1):333-339.	
	R42	SABIN, A.B. and BOULGER, L.R. "History of Sabin attenuated poliovirus oral live vaccine strains" <i>J. of Biol. Standardization</i> , 1973, 1:115-118.	
	R43	SAMULSKI, R.J. et al. "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression" <i>J. Vir.</i> , 1989, 63(9):3822-3828.	
	R44	STEPHENS, L.R. et al. "Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signaling system?" <i>Biochim. Biophys Acta</i> , 1993, 1179:27-75.	
	R45	TAMM, I. et al. "Antisense therapy in oncology: new hope for an old idea?" <i>The Lancet</i> , 2001, 358:489-497.	
	R46	WANG, C.Y. and HUANG, L. "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse" <i>PNAS</i> , 1987, 84:7851-7855.	
	R47	WANG, J-W. et al. "Influence of ZSHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation" <i>Science</i> , 2002, 295(5562):2094-2097.	
	R48	WOLF, I. et al. "Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIP6" <i>Genomics</i> , 2000, 69(1):104-112.	
	R49	YOKOYAMA, W.M. "Natural killer cell receptors" <i>Current Opin in Immunology</i> , 1998, 10(3):298-305.	
	R50		
	R51		
	R52		

Examiner Signature	Q3	Date Considered	11-10-07
--------------------	----	-----------------	----------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

8/21/07

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Desponts
				Group Art Unit	1635
				Examiner Name	Jane J. Zara
				Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
J 3	R1	KERR, W.G. et al. "The SH2 Containing Inositol Phosphatase (SHIP) is a Crucial Regulator of NK Cell Repertoire and Function" Abstract #34, presented at Core Research for Evolutional Science and Technology (CREST) International Symposium on Immunoglobulin-like Receptors, held September 19-20, 2000, at the Sendai International Center, Sendai City, Japan.		
J 3	R2	Statement of Dr. Toshiyuki Takai, an organizer of the CREST International Symposium on Immunoglobulin-like Receptors, held September 19-20, 2000.		
J 3	R3	Program and Abstracts for CREST International Symposium on Immunoglobulin-like Receptors, held September 19-20, 2000.		
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			
	R			

Examiner Signature	J 3	Date Considered	11-10-07
--------------------	-----	-----------------	----------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.